Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors — Linda Y. Wu (2024) | RDL Network
Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors
BJC Reports 2(1)
Article 2024 English
Authors
LW
Linda Y. Wu
SC
Sarah Cappuyns
AL
Amanda S. Loh
Abstract
1 min read
Immune checkpoint inhibitors (ICIs) are standard therapy for unresectable HCC, but many patients do not respond. Non-viral HCC, particularly non-alcoholic steatohepatitis (NASH), have been implicated in ICI resistance.
Li Gu, Yahui Zhu, Maiya Lee, Albert Nguyen, Nicolas T. Ryujin, Jian Yu Huang, Shusil K. Pandit, Shadi Chamseddine, Lianchun Xiao, Yehia I. Mohamed, Ahmed O. Kaseb, Michael Karin, Shabnam Shalapour
Discussion(0)
No comments yet. Be the first to comment.